Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study

BACKGROUND. Sodium glucose cotransporter-2 (SGLT2) inhibitors are the most recently approved class of drugs for type 2 diabetes and provide both glycemic efficacy and cardiovascular risk reduction. A number of safety issues have been identified, including treatment-emergent bone fractures. To unders...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:JCI Insight
Päätekijät: Blau, Jenny E., Bauman, Viviana, Conway, Ellen M., Piaggi, Paolo, Walter, Mary F., Wright, Elizabeth C., Bernstein, Shanna, Courville, Amber B., Collins, Michael T., Rother, Kristina I., Taylor, Simeon I.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society for Clinical Investigation 2018
Aiheet:
Clinical Medicine
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5931122/
https://ncbi.nlm.nih.gov/pubmed/29669938
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.99123
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia